Related Experiment Video

Updated: Jun 17, 2026

Hydrophobic Salt-modified Nafion for Enzyme Immobilization and Stabilization
11:16

Hydrophobic Salt-modified Nafion for Enzyme Immobilization and Stabilization

Published on: July 11, 2012

Talaporfin sodium

S Wang1, Elizabeth Bromley, Leon Xu

  • 1Light Sciences Oncology, 15405 SE 37th Street, Suite 100, Bellevue, WA 98006, USA. syshiw@lsoncology.com

Expert Opinion on Pharmacotherapy
|December 17, 2009
PubMed
Abstract

Insights

Talaporfin sodium, a light-activated drug, shows promise for cancer treatment. It may work alone or with other therapies, offering a new option for patients.

Area of Science:

  • Oncology
  • Photodynamic Therapy
  • Cancer Therapeutics

Background:

  • Cancer remains a leading cause of death in the USA, necessitating novel therapeutic strategies.
  • Existing treatments have limitations, driving the need for innovative approaches to combat malignancy.

Purpose of the Study:

  • To review the therapeutic potential of talaporfin sodium for various cancers.
  • To summarize its mechanism of action, clinical trial data, and safety profile.

Main Methods:

  • Talaporfin sodium is a photosensitive drug inducing apoptosis and systemic antitumor effects via CD8(+) T cells.
  • Clinical trials have evaluated its efficacy in early-stage endobronchial cancer, solid tumors, hepatocellular carcinoma, and liver-metastatic colorectal cancer.
  • Studies also explore its use in benign prostatic hyperplasia.

Main Results:

  • Talaporfin sodium demonstrates tumor regression in patients refractory to other treatments.
  • It exhibits a favorable safety profile and is well-tolerated in clinical trials.
  • The drug's mechanism suggests potential for affecting both treated and untreated tumors.

Conclusions:

  • Talaporfin sodium presents a viable therapeutic option for cancer treatment.
  • It may serve as a synergistic agent with current therapies or as a standalone monotherapy.
  • Further clinical studies are ongoing to establish its role in diverse oncological settings.

More Related Videos

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles09:51

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles

Published on: September 17, 2013

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins11:30

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

Related Concept Videos

Porin Insertion in the Outer Mitochondrial Membrane01:12

Porin Insertion in the Outer Mitochondrial Membrane

Porins are beta-barrel proteins translocated to the mitochondrial outer membrane through the TOM complex into the intermembrane space. Porin precursors bind TIM chaperones within the intermembrane space and are guided to the Sorting and Assembly Machinery complex or SAM complex on the outer mitochondrial membrane.
Three models describe the assembly of porins by the SAM complex and their insertion into the outer membrane. Model 1 suggests that porins are assembled outside the SAM channel as the...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Structure of Porins01:21

Structure of Porins

Mitochondria, chloroplasts, and gram-negative bacteria have transmembrane, beta-barrel proteins called porins to mediate the free diffusion of ions and metabolites across the membrane. Mitochondrial porin precursors contain conserved amino acid sequences called beta signals at their C-terminal. Beta signals have a  motif of PoXGXXHyXHy (Po-Polar, X-Any amino acid, G-Glycine, Hy-LargeHydrophobic), which are crucial for precursor recognition to initiate precursor assembly. Beta-barrel precursors...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pore Transport and Ion-Pair Transport01:17

Pore Transport and Ion-Pair Transport

Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited  but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...